 |
|
 |
Medical Devices |
|
|
United States Drug Delivery Devices Medical Equipment Industry Report
Detailed Analysis of the Medical Equipment & Medical Devices Market Covering Infusion Systems, Inhalation Systems and Needle Free Injections Medical Equipment and Supplies
Publication Date April 2008
Publisher Global Markets Direct
Product Type Report
Pages 295
ISBN Number not applicable
Product Code GMD470
|
|
|
Summary
United States Drug Delivery Devices Medical Equipment Industry Report
Summary
This report is an essential source for in-depth information and data relating to United States drug delivery devices medical equipment market. It also offers detailed and comprehensive coverage of market revenue, volume, distribution and company share information; and latest news, financial deals and pipeline products information of each of the key sub-segments of the drug delivery devices medical equipment in United States.
Scope
- The report provides sector information broken down into detailed categories and segments in country.
- Total revenues, products sold, end users, and average pricing.
- Market shares of all the key competitors.
- Key pipeline products that are set to shape the market, broken down by sector.
- Information on the top medical equipment companies in the sector in the country covering business description, strategic analysis, and financial information.
- Healthcare structure, regulatory environment, approval process, pricing trends and reimbursement.
- Product and brand updates, strategy changes, R&D projects, corporate expansions and contractions and regulatory changes.
- Key mergers and acquisitions, partnerships, private equity investments and IPOs.
- Customer, hospitals and physicians data.
Reasons to buy
- Gain a strong understanding of the industry at a global level, with break downs for the country
- Evaluate and compare the attractiveness of the market in the country.
- Identify growth segments and opportunities in each industry sector within the country.
- Evaluate the pipeline of key products that will change the sector, and identify threats and opportunities before the products are launched in the country.
- Analyze the competitiveness of the market in the country and identify hotspots.
- Develop strategies based on the latest product, brand, expansion and research and development news in the country.
- Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the market in the country.
- Identify and analyze the strengths and weaknesses of the industry incumbents in the country.
|
Content
- 1 Table Of Contents
- 1.1 List Of 1.2 List Of 2 Introduction
- 2.1 What Is This Report About?
- 2.2 Definitions
- 2.2.1 Drug delivery devices
- 2.2.1.1 Needle-free Injections
- 2.2.1.2 Inhalation Systems
- 2.2.1.3 Infusion Systems
- 3 Healthcare Sector Review
- 3.1 Healthcare Expenditure
- 3.2 Healthcare Infrastructure
- 3.2.1 Healthcare Personnel Data
- 3.2.2 Healthcare Facilities Data
- 4 Drug Delivery Devices in United States
- 4.1 Drug Delivery Devices Overall Revenues (2000-2012)
- 4.2 Drug Delivery Devices Overall Volume (2000-2012)
- 4.3 Drug Delivery Devices Overall Company Shares (2005-2006)
- 5 Inhalation System in United States
- 5.1 Inhalation Systems Overall Revenues (2000-2012)
- 5.1.1 Metered Dose Inhalation Systems Overall Revenues (2000-2012)
- 5.1.2 Dry Powder Inhalation Systems Overall Revenues (2000-2012)
- 5.2 Inhalation Systems Overall Volume (2000-2012)
- 5.2.1 Metered Dose Inhalation Systems Overall Volume (2000-2012)
- 5.2.2 Dry Powder Inhalation Systems Overall Volume (2000-2012)
- 5.3 Inhalation Systems Average Price (2000-2012)
- 5.3.1 Metered Dose Inhalation Systems Average Price (2000-2012)
- 5.3.2 Dry Powder Inhalation Systems Average Price (2000-2012)
- 5.4 Inhalation Systems Distribution Share (2005-2006)
- 5.5 Inhalation Systems Company Share (2005-2006)
- 6 Infusion System in United States
- 6.1 Infusion Systems Overall Revenues (2000-2012)
- 6.1.1 Infusion Disposable Sets Infusion System Overall Revenues (2000-2012)
- 6.1.2 Infusion Pumps Infusion System Overall Revenue (2000-2012)
- 6.1.3 Syringe Pumps Infusion System Overall Revenue (2000-2012)
- 6.2 Infusion Systems Overall Volume (2000-2012)
- 6.2.1 Infusion Disposable Sets Overall Volume (2000-2012)
- 6.2.2 Infusion Pumps Overall Volume (2000-2012)
- 6.2.3 Syringe Pumps Overall Volume (2000-2012)
- 6.3 Infusion Systems Average Price (2000-2012)
- 6.3.1 Infusion Pumps Average Price (2000-2012)
- 6.3.2 Syringe Pumps Average Price (2000-2012)
- 6.3.3 Infusion Disposable Sets Average Price (2000-2012)
- 6.4 Infusion Systems Distribution Share (2005-2006)
- 6.5 Infusion Systems Company Share (2005-2006)
- 7 Needle Free Injections in United States
- 7.1 Needle Free Injections Overall Revenue (2000-2012)
- 7.2 Needle Free Injections Category Volume (2000-2012)
- 7.3 Needle Free Injections Average Price (2000-2012)
- 7.4 Needle Free Injections Distribution Share (2005-2006)
- 7.5 Needle Free Injections Company Share (2005-2006)
- 8 AstraZeneca PLC Company Profile
- 8.1 Company Overview
- 8.2 Business Overview
- 8.2.1 Products
- 8.2.2 History
- 8.3 Locations And Subsidiaries
- 8.4 Financial Deals Landscape
- 8.4.1 AstraZeneca Completes $6,900 Million Private Placement
- 8.4.2 AstraZeneca Acquires MedImmune
- 8.4.3 AstraZeneca Acquires Biologics Manufacturing Facility From DSM Biologics
- 8.4.4 AstraZeneca Acquires Arrow Therapeutics
- 8.4.5 AstraZeneca Signs An Agreement With Palatin Technologies
- 8.4.6 AstraZeneca Signs An Agreement With Bristol-Myers Squibb
- 8.4.7 AstraZeneca Signs An Agreement With Cubist Pharmaceuticals
- 8.4.8 AstraZeneca Signs An Agreement With Par Pharmaceutical
- 8.4.9 Schering Signs An Agreement With AstraZeneca
- 8.4.10 AstraZeneca Signs An Agreement With Pozen
- 8.4.11 AstraZeneca Signs An Agreement With Abbott
- 8.4.12 AstraZeneca To Sell Its U.S Anaesthetic and Analgesic Product Portfolio To Abraxis BioScience
- 8.4.13 AstraZeneca Acquires KuDOS Pharmaceuticals
- 8.4.14 AstraZeneca Acquires A Stake In Protherics
- 8.4.15 AstraZeneca Signs An Agreement With Targacept
- 8.4.16 AstraZeneca Signs An Agreement With AtheroGenics
- 8.4.17 AstraZeneca UK Signs An Agreement With Protherics
- 8.4.18 AstraZeneca Signs An Agreement With Bayer Schering Pharma Aktiengesellschaft
- 8.4.19 AstraZeneca Signs An Agreement With Astex Therapeutics
- 8.4.20 AstraZeneca Signs An Agreement With Avanir Pharmaceuticals
- 8.4.21 AstraZeneca And Royal Cosun Sells Joint Venture Advanta To Syngenta
- 8.4.22 AstraZeneca Completes Private Placement Of $750 million
- 8.4.23 AstraZeneca Prices EUR750 Million Private Placement
- 8.4.24 AstraZeneca Prices Sterling Bond GBP350 Million And Euro750 Million Eurobond Private Placement
- 8.5 Recent Developments
- 8.5.1 Feb 22, 2008: AstraZeneca To Appeal Judgment In Alabama Medical Pricing Case
- 8.5.2 Feb 18, 2008: AstraZeneca Appoints Non-Executive Director
- 8.5.3 Dec 12, 2007: AstraZeneca Files Patent Infringement Actions in Response to Crestor ANDAs
- 8.5.4 Sep 28, 2007: AstraZeneca Appoints New CFO
- 8.5.5 Jul 25, 2007: AstraZeneca Appoints New Board Member
- 8.5.6 Jun 06, 2007: AstraZeneca CFO Resigns
- 8.5.7 Feb 22, 2007: AstraZeneca To Invest $120 Miilion For R&D In Macclesfield Site
- 8.5.8 Jan 30, 2007: Philips And Leading Healthcare Companies Join For Major Research And Development
- 8.5.9 Jan 22, 2007: AstraZeneca Makes $100 Million Research Investment In Boston
- 9 GlaxoSmithKline plc Company Profile
- 9.1 Company Overview
- 9.2 Business Overview
- 9.2.1 Products
- 9.2.2 History
- 9.3 Locations And Subsidiaries
- 9.4 Financial Deals Landscape
- 9.4.1 GlaxoSmithKline Acquires CNS
- 9.4.2 Bayer HealthCare Acquires Pritor Business From GlaxoSmithKline
- 9.4.3 CNS To Merge With GlaxoSmithKline
- 9.5 Recent Developments
- 9.5.1 Mar 19, 2008: GSK charitable support valued at GBP282 million in 2007
- 9.5.2 Feb 07, 2008: Full-year results announcement 2007
- 9.5.3 Dec 19, 2007: GlaxoSmithKline And Santaris Enter Global R&D Alliance
- 9.5.4 Dec 10, 2007: GlaxoSmithKline And OncoMed Form Strategic Alliance To Develop Cancer Stem Cell Antibody Therapeutics
- 9.5.5 Dec 07, 2007: GlaxoSmithKline Announces Board And Management Changes
- 10 3M Company Profile
- 10.1 Company Overview
- 10.2 Business Overview
- 10.2.1 Consumer and Office
- 10.2.2 Display and Graphics
- 10.2.3 Electro and Communications
- 10.2.4 Health Care
- 10.2.5 Industrial and Transportation
- 10.2.6 Safety, Security and Protection Services
- 10.2.7 Products
- 10.3 Value Chain Analysis
- 10.3.1 Manufacturing
- 10.3.2 Product Development
- 10.3.3 Sales and Marketing
- 10.4 SWOT Analysis
- 10.4.1 3M Company Strengths
- 10.4.2 3M Company Weaknesses
- 10.4.3 3M Company Opportunities
- 10.4.4 3M Company Threats
- 10.5 Financial and Operational Review
- 10.6 Locations And Subsidiaries
- 10.7 Financial Deals Landscape
- 10.7.1 3M Canada Acquires Les Entreprises Solumed
- 10.7.2 3M Acquires Bondo
- 10.7.3 3M Acquires Lingualcare
- 10.7.4 3M Acquires Abzil Industria E Comercio
- 10.7.5 3M Acquires Neo Plast
- 10.7.6 3M Acquires Assets Of DMS Chile
- 10.7.7 3M Acquires Business Of Innovative Paper Technologies
- 10.7.8 3M Acquires Powell
- 10.7.9 Gen-Probe Signs An Agreement With 3M Company
- 10.7.10 3M Acquires Acolyte Biomedica
- 10.7.11 3M Acquires Sealed Air Corp.'S Interest In Polymask Corp
- 10.7.12 3M Sells Its Pharmaceutical Business To Meda AB
- 10.7.13 3M Acquires SoftMed Systems
- 10.7.14 3M Sells its Pharmaceuticals Business to Graceway
- 10.7.15 Gen-Probe Signs An Agreement With 3M
- 10.7.16 3M Sells its Pharmaceutical Operations in the Asia Pacific Region to Ironbridge Capital and Archer Capital
- 10.7.17 3M Acquires Biotrace International
- 10.7.18 Ekahau Secures $16 Million In Additional Funding
- 10.7.19 3M Acquires Brontes Technologies
- 10.7.20 3M acquires Nylonge Corp
- 10.7.21 3M Signs An Agreement With ClozeX Medical
- 10.7.22 3M Acquires OMNII Oral Pharmaceuticals
- 10.7.23 3M Sells Pharmaceutical Operations In The United States To Graceway
- 10.7.24 3M Sells Pharmaceutical Business In Europe To Meda AB
- 10.7.25 3M Sells Pharmaceutical Operations In The Asia Pacific To Ironbridge and Archer Capital
- 10.7.26 3M Acquires Accuspray Application Technologies Inc
- 10.7.27 3M to acquire Rochford Thompson Equipment
- 10.7.28 3M To Acquire Aearo Technologies From Permira
- 10.7.29 Permira To Sell Aearo Technologies To 3M
- 10.8 Recent Developments
- 10.8.1 Mar 31, 2008: HighJump Software Introduces Survey Management Solution for Direct Store Delivery Businesses
- 10.8.2 Mar 24, 2008: Brazil's Companhia de Transmissao de Energia Eletrica Paulista Chooses 3M ACCR for Upgrade of Line Over Parana River in Sao Paulo State
- 10.8.3 Mar 19, 2008: 3M to Headquarter Optical Systems Business in Asia
- 10.8.4 Mar 19, 2008: 3M To Headquarter Optical Systems Business In North Asia
- 10.8.5 Nov 12, 2007: 3M Declares Quarterly Dividend
- 10.8.6 Oct 24, 2007: 3M And Sanyo Settle Suit On Lithium Ion Battery
- 10.8.7 Aug 13, 2007: 3M Declares Quarterly Dividend
- 10.8.8 May 08, 2007: 3M Declares Quarterly Dividend
- 10.8.9 Apr 30, 2007: Gen-Probe And 3M Collaborate To Develop Rapid Molecular Tests
- 11 Baxter International Company Profile
- 11.1 Company Overview
- 11.2 Business Overview
- 11.2.1 BioScience
- 11.2.2 Medication Delivery
- 11.2.3 Renal
- 11.2.4 Products
- 11.2.5 History
- 11.3 Value Chain Analysis
- 11.3.1 Manufacturing
- 11.3.2 Product Development
- 11.3.3 Sales and Marketing
- 11.4 SWOT Analysis
- 11.4.1 Baxter International Inc. Strengths
- 11.4.2 Baxter International Inc. Weaknesses
- 11.4.3 Baxter International Inc. Opportunities
- 11.4.4 Baxter International Inc. Threats
- 11.5 Financial and Operational Review
- 11.6 Locations And Subsidiaries
- 11.7 Financial Deals Landscape
- 11.7.1 Baiyunshan And Baxter Form A Joint Venture In China
- 11.7.2 Baxter Signs Licensing Agreement With Intercytex And Spinal Restoration
- 11.7.3 Baxter Sells Transfusion Therapies Business to Texas Pacific and Maverick Capital
- 11.7.4 B. Braun Acquires Renal Therapy Business Of Baxter
- 11.7.5 Innovata signs a license agreement with Baxter International
- 11.7.6 Kuros Biosurgery Signs An Agreement With Baxter International
- 11.7.7 Gambro Signs An Agreement With Baxter
- 11.7.8 Baxter Healthcare And Gambro Enter Into An Agreement
- 11.7.9 Baxter and Cerus Enter Into Agreement With BioOne for Commercialization Of INTERCEPT Blood System
- 11.7.10 Baxter International And Kaketsuken Enter Into Agreement
- 11.7.11 Baxter To Acquire 40% Stake In Shanghai Baxter From Worldbest Treeful
- 11.8 Recent Developments
- 11.8.1 Jan 24, 2008: Baxter Achieves Record Sales and Earnings for Full-Year 2007
- 11.8.2 Dec 18, 2007: Baxter Elects CFO
- 11.8.3 Nov 13, 2007: Baxter Declares Quarterly Dividend
- 11.8.4 Aug 01, 2007: Baxter Elects New Board Director
- 11.8.5 Jul 31, 2007: Baxter Announces Quarterly Dividend
- 11.8.6 Mar 13, 2007: Baxter Declares Additional Share Repurchase Authorization
- 11.8.7 Feb 13, 2007: Baxter Announces Quarterly Dividend
- 11.8.8 Nov 28, 2006: Baxter Announces Annual Dividend
- 11.8.9 Sep 14, 2006: Baxter Appoints President, Baxter Latin America
- 11.9 Baxter International Inc. Pipeline Products
- 11.9.1 Next-Generation Home Hemodialysis Machine
- 11.9.1.1 Product Overview
- 11.9.1.2 Product Description
- 11.9.1.3 Product Status
- 11.9.1.4 Product Milestone
- 12 Hospira Company Profile
- 12.1 Company Overview
- 12.2 Business Overview
- 12.2.1 Injectable Pharmaceutical Custom Manufacturing Services Product Category
- 12.2.2 Other products, including critical care devices Product Category
- 12.2.3 Specialty Injectable Pharmaceuticals Product Category
- 12.2.4 Products
- 12.3 History
- 12.4 Value Chain Analysis
- 12.4.1 Manufacturing
- 12.4.2 Product Development
- 12.4.3 Sales and Marketing
- 12.5 SWOT Analysis
- 12.5.1 Hospira, Inc. Strengths
- 12.5.2 Hospira, Inc. Weaknesses
- 12.5.3 Hospira, Inc. Opportunities
- 12.5.4 Hospira, Inc. Threats
- 12.6 Financial and Operational Review
- 12.7 Locations And Subsidiaries
- 12.8 Financial Deals Landscape
- 12.8.1 Hospira Acquires Mayne Pharma
- 12.8.2 Hospira Signs An Agreement With STADA
- 12.8.3 Hospira Acquires Physiometrix
- 12.8.4 ICU Medical Acquires Salt Lake City Manufacturing Facility From Hospira
- 12.9 Recent Developments
- 12.9.1 Feb 28, 2007: Hospira Reports 2006 Results
- 12.9.2 Oct 31, 2006: Hospira Elects New Board Member
- 12.9.3 Aug 11, 2006: Hospira Appoints New CFO
- 13 Regulation System
- 13.1 Medical Equipment Approval Process
- 13.1.1 Pre-market Approval Process
- 13.1.2 Intended use and Indications for use
- 13.1.3 Predicate Device
- 13.1.4 Safe and Effective
- 13.1.5 Other Category Devices
- 13.1.6 Post-Market Approval Process
- 13.1.7 Compliance and Enforcement
- 13.1.8 Registration Fee
- 13.1.9 Approval Time
- 14 Pricing and Reimbursement
- 14.1 Government Policies
- 14.2 Private Insurance
- 14.3 Diagnosis Related Groups (DRG)
- 15 Distribution Structure
- 15.1 Distribution Structure
- 16 APPENDIX
- 16.1 Methodology
- 16.2 Currency Conversion
- 16.3 Contact Us
- 16.4 Disclaimer
|
|
|
